Ipsen Boosts Rare Disease Portfolio with Clementia Acquisition
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 3 (Table of Contents)
Published: 7 Mar-2019
DOI: 10.3833/pdr.v2019.i3.2409 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a move to bolster its rare disease business, Ipsen has agreed to acquire Clementia Pharmaceuticals for up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS